



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AIMOVIG® (erenumab-aooe)	Neuroscience	Pediatric Migraine	Monoclonal Antibody	3
DESCRIPTION Aimovig® inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients.				
BLINCYTO® (blinatumomab)	Hematology/Oncology	Pediatric Acute Lymphoblastic Leukemia	BiTE® Construct	3
DESCRIPTION BLINCYTO® is an anti-CD 19 (cluster of differentiation 19) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients at first relapse.				
EVENITY® (romosozumab-aqqg)	Bone	Male Osteoporosis	Monoclonal Antibody	3
DESCRIPTION EVENITY® is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of male osteoporosis.				
IMLYGIC® (talimogene laherparepvec)	Hematology/Oncology	Metastatic Melanoma	Oncolytic Immunotherapy	3
DESCRIPTION IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is being investigated for the treatment of melanoma in combination with pembrolizumab.				
KYPROLIS® (carfilzomib)	Hematology/Oncology	Multiple Myeloma	Small Molecule	3
DESCRIPTION KYPROLIS® is a small molecule proteasome inhibitor (PI). It is being investigated in the ARROW-2 study for weekly dosing in combinations with lenalidomide and dexamethasone for relapsed multiple myeloma.				

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
NPLATE® (romiplostim)	Hematology/Oncology	Multiple Myeloma	Small Molecule	3
	DESCRIPTION KYPROLIS® is a small molecule proteasome inhibitor (PI). It is being investigated in the CANDOR study in combination with dexamethasone and DARZALEX® (daratumumab) compared to KYPROLIS® and dexamethasone alone.			
	ADDITIONAL INFORMATION DARZALEX is a registered trademark of Janssen Biotech, Inc.			
NPLATE® (romiplostim)	Hematology/Oncology	Chemotherapy-Induced Thrombocytopenia	Peptibody	3
	DESCRIPTION Nplate® is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of in chemotherapy-induced thrombocytopenia (CIT).			
	Hematology/Oncology	Early ITP	Peptibody	3
	DESCRIPTION Nplate® is a thrombopoietin receptor agonist (TPO-RA). It is being investigated in early immune thrombocytopenia purpura (ITP).			
	Hematology/Oncology	Acute Radiation Syndrome (ARS)	Peptibody	3
	DESCRIPTION Nplate® is a thrombopoietin receptor agonist (TPO-RA). It is being investigated in hematopoietic syndrome of acute radiation syndrome (ARS).			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
OMECAMTIV MECARBIL	Cardiometabolic	Heart Failure	Small Molecule	3
	DESCRIPTION Omeamtiv mecarbil is a small molecule selective cardiac myosin activator, or myotrope, which directly targets the contractile mechanisms of the heart. It is being investigated for the treatment of heart failure.			
	ADDITIONAL INFORMATION Omeamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier.			
	Cardiometabolic	Pediatric Heart Failure	Small Molecule	1
OTEZLA® (apremilast)	Inflammation	Pediatric Plaque Psoriasis	Small Molecule	3
	DESCRIPTION Otezla® is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe plaque psoriasis in pediatric patients.			
	Inflammation	Mild to Moderate Plaque Psoriasis	Small Molecule	3
	DESCRIPTION Otezla® is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of mild to moderate plaque psoriasis.			
	Inflammation	Genital Psoriasis	Small Molecule	3
	DESCRIPTION Otezla® is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe genital psoriasis.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
	Inflammation	Juvenile Psoriatic Arthritis	Small Molecule	3
	DESCRIPTION Otezla® is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of juvenile psoriatic arthritis in pediatric patients.			
	Inflammation	Pediatric Behcet's Disease	Small Molecule	3
	DESCRIPTION Otezla® is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of Behcet's disease in pediatric patients.			
PARSABIV® (etelcalcetide)	Nephrology	Pediatric Secondary Hyperparathyroidism	Peptide	3
	DESCRIPTION Parsabiv® is a calcium-sensing receptor agonist. It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease (CKD) receiving hemodialysis.			
PROLIA® (denosumab)	Bone	Pediatric Glucocorticoid-Induced Osteoporosis	Monoclonal Antibody	3
	DESCRIPTION Prolia® is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients.			
	Bone	Pediatric Osteogenesis Imperfecta	Monoclonal Antibody	3
	DESCRIPTION Prolia® is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
REPATHA® (evolocumab)	Cardiometabolic	Hypercholesterolemia	Monoclonal Antibody	3
	DESCRIPTION Repatha® is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated in VESALIUS – CV study in high-risk cardiovascular disease patients without prior heart attack or stroke.			
	Cardiometabolic	Pediatric Familial Hypercholesterolemia	Monoclonal Antibody	3
	DESCRIPTION Repatha® is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated in pediatric patients with familial hypercholesterolemia (FH).			
SOTORASIB (Pending INN for AMG 510)	Hematology/Oncology	Non-Small Cell Lung Cancer	Small Molecule	3
	DESCRIPTION Sotorasib (pending INN for AMG 510) is a KRAS ^{G12C} small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.			
	Hematology/Oncology	Advanced Colorectal Cancer	Small Molecule	2
	DESCRIPTION Sotorasib (pending INN for AMG 510) is a KRAS ^{G12C} small molecule inhibitor under investigation for the treatment of advanced colorectal cancer.			
	Hematology/Oncology	Other Tumors	Small Molecule	2
	DESCRIPTION Sotorasib (pending INN for AMG 510) is a KRAS ^{G12C} small molecule inhibitor under investigation for the treatment of advanced solid tumors other than non-small cell lung cancer or advanced colorectal cancer.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
TEZEPELUMAB	Inflammation	Severe Asthma	Monoclonal Antibody	3
	DESCRIPTION Tezepelumab is a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated in the NAVIGATOR and SOURCE studies for the treatment of severe asthma.			
	ADDITIONAL INFORMATION In September 2018, we announced that the FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype. Tezepelumab is being developed in collaboration with AstraZeneca plc.			
	Inflammation	Chronic Obstructive Pulmonary Disease	Monoclonal Antibody	2
ABP 654 (biosimilar STELARA®)				3
	DESCRIPTION ABP 654 (ustekinumab), a biosimilar candidate to STELARA®, is a monoclonal antibody that inhibits IL-12 and IL-23.			
	ADDITIONAL INFORMATION STELARA® is a registered trademark of Johnson & Johnson.			
ABP 798 (biosimilar Rituxan®/MabThera™)	Hematology/Oncology	Rituxan® /MabThera™ biosimilarity	Monoclonal Antibody	3
	DESCRIPTION ABP 798 (rituximab), a biosimilar candidate to Rituxan®/MabThera™, is an anti-CD20 monoclonal antibody.			
	ADDITIONAL INFORMATION Amgen has been developing ABP 798 in collaboration with Allergan since 2011. Allergan was acquired by AbbVie in May 2020. Rituxan® is a registered trademark of Biogen MA Inc. MabThera™ is a trademark of F. Hoffmann-La Roche Ltd.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
ABP 938 (biosimilar EYLEA®)	Inflammation	EYLEA® biosimilarity	Fusion Protein	3
DESCRIPTION ABP 938 (afibercept), a biosimilar candidate to EYLEA®, is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.				
ADDITIONAL INFORMATION EYLEA® is a registered trademark of Regeneron Pharmaceuticals, Inc.				
ABP 959 (biosimilar Soliris®)	Hematology/Oncology	Soliris® biosimilarity	Monoclonal Antibody	3
DESCRIPTION ABP 959 (eculizumab), a biosimilar candidate to Soliris®, is a monoclonal antibody that specifically binds to the complement protein C5.				
ADDITIONAL INFORMATION Soliris® is a registered trademark of Alexion Pharmaceuticals Inc.				
OLPASIRAN (formerly AMG 890)	Cardiometabolic	Cardiovascular Disease	siRNA	2
DESCRIPTION Olpasiran (formerly known as AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease.				
ROZIBAFUSP ALFA (formerly AMG 570)	Inflammation	Systemic Lupus Erythematosus	Bispecific Antibody	2
DESCRIPTION Rozibafusp alfa (formerly AMG 570) is a novel bispecific antibody-peptide conjugate that simultaneously blocks ICOSL and BAFF activity. It is being investigated for the treatment of systemic lupus erythematosus.				

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 714 / PRV-015	Inflammation	Celiac Disease	Monoclonal Antibody	2
	DESCRIPTION AMG 714 is a human monoclonal antibody that binds to Interleukin-15 (IL-15). It is being investigated for the treatment of celiac disease.			
	ADDITIONAL INFORMATION AMG 714 (also known as PRV-015) is being developed in collaboration with Provention Bio.			
AMG 119	Hematology/Oncology	Small Cell Lung Cancer	CAR-T	1
	DESCRIPTION AMG 119 is a delta-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T cell) cellular therapy. It is being investigated for the treatment of small-cell lung cancer.			
AMG 133	Cardiometabolic	Obesity	Antibody-Peptide Conjugate	1
	DESCRIPTION AMG 133 is a gastric inhibitory polypeptide receptor (GIPR) antagonist and GLP-1R agonist. It is being investigated for the treatment of obesity.			
AMG 160	Hematology/Oncology	Prostate Cancer	BiTE® Construct	1
	DESCRIPTION AMG 160 is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of prostate cancer.			
AMG 171	Cardiometabolic	Obesity	Fusion Protein	1
	DESCRIPTION AMG 171 is a Growth Differential Factor 15 (GDF15) analog. It is being investigated for the treatment of obesity.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 176	Hematology/Oncology	Hematology	Small Molecule	1
	DESCRIPTION AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.			
AMG 199	Hematology/Oncology	Metastatic gastric and Gastroesophageal junction cancer	BiTE® Construct	1
	DESCRIPTION AMG 199 is a half-life extended (HLE) anti-MUC17 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of gastric and gastroesophageal junction cancer.			
AMG 256	Hematology/Oncology	Solid Tumors	Fusion Protein Conjugate	1
	DESCRIPTION AMG 256 (anti-PD-1 x IL21 mutein) is a targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells. It is being investigated for the treatment of solid tumors.			
AMG 330	Hematology/Oncology	Acute Myeloid Leukemia	BiTE® Construct	1
	DESCRIPTION AMG 330 is an anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of acute myeloid leukemia.			
AMG 397	Hematology/Oncology	Hematology	Small Molecule	1
	DESCRIPTION AMG 397 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 404	Hematology/Oncology	Solid Tumors	Monoclonal Antibody	1
	DESCRIPTION AMG 404 is a human anti-programmed cell death-1 (PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.			
AMG 427	Hematology/Oncology	Acute Myeloid Leukemia	BiTE® Construct	1
	DESCRIPTION AMG 427 is a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of acute myeloid leukemia.			
AMG 506	Hematology/Oncology	Solid Tumors	DARPin® protein	1
	DESCRIPTION AMG 506 is a multi-specific FAP x 4-1BB-targeting DARPin® biologic under investigation as a treatment for solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules. ADDITIONAL INFORMATION AMG 506 (also known as MP0310) is being developed in collaboration with Molecular Partners AG. DARPin® is a registered trademark owned by Molecular Partners AG.			
AMG 509	Hematology/Oncology	Prostate Cancer	XmAb® Antibody	1
	DESCRIPTION AMG 509 (STeAP1 XmAb® antibody) is a bivalent T-cell engager and is designed using XmAb® 2+1 technology. It is being investigated for the treatment of prostate cancer. ADDITIONAL INFORMATION XmAb® is a registered trademark of Xencor, Inc.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
EFAVALEUKIN ALFA (formerly AMG 592)	Inflammation	Inflammatory Diseases	Fusion Protein	1
	DESCRIPTION Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of inflammatory diseases.			
AMG 594	Cardiometabolic	Heart Failure	Small Molecule	1
	DESCRIPTION AMG 594 is a selective small molecule cardiac troponin activator being developed to improve cardiac muscle function, directly targeting the loss of contractility. ADDITIONAL INFORMATION AMG 594 was discovered under a joint research program conducted between Amgen and Cytokinetics.			
AMG 596	Hematology/Oncology	Glioblastoma	BiTE® Construct	1
	DESCRIPTION AMG 596 is a CD3 x epidermal growth factor receptor vIII (EGFRvIII) BiTE® (bispecific T cell engager) molecule. AMG 596 is being investigated for the treatment of glioblastoma.			
AMG 650	Hematology/Oncology	Solid Tumors	Small Molecule	1
	DESCRIPTION AMG 650 is an orally-administered small molecule being evaluated in advanced solid tumors.			
AMG 673	Hematology/Oncology	Acute Myeloid Leukemia	BiTE® Construct	1
	DESCRIPTION AMG 673 is a half-life extended (HLE) anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of acute myeloid leukemia.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 701	Hematology/Oncology	Multiple Myeloma	BiTE® Construct	1
	DESCRIPTION AMG 701 is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of multiple myeloma.			
AMG 757	Hematology/Oncology	Small Cell Lung Cancer	BiTE® Construct	1
	DESCRIPTION AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of small-cell lung cancer.			
AMG 910	Hematology/Oncology	Gastric Cancer and Gastroesophageal Junction Cancer	BiTE® Construct	1
	DESCRIPTION AMG 910 is a half-life extended (HLE) anti-CLDN18.2 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of gastric and gastroesophageal junction cancer.			

‡ In addition to the above programs, AMJEVITA™/AMGEVITA™, MVASI™, and KANJINTI™ have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA™ has been approved by the FDA.

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of October 28, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.